George Cornett, MD
Internal Medicine · Franklin, INNPI 1902808199
Payments from drug & device makers
What this record shows
Eli Lilly accounts for 72.5% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2024 at $2,319 and has fallen 95.3% since, to $108 in 2025. Among internal medicine clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 100 payments — averaging $43.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$3K
- Novo Nordisk$190
- GSK$170
- AstraZeneca$124
- Exact Sciences$108
- Pfizer$92
- plus $505 from 19 others
Across 797 payments — averaging $1767.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$730K
- Novo Nordisk AS$332K
- AbbVie$165K
- AstraZeneca$42K
- Alnylam Pharmaceuticals Inc.$40K
- Astrazeneca UK Limited$21K
- plus $79K from 9 others
What the payments were for
- Travel & lodging$2,38755%
- Food & beverage$1,93845%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 21 | $3,136 |
| Novo Nordisk | 16 | $190 |
| GSK | 12 | $170 |
| AstraZeneca | 4 | $124 |
| Exact Sciences | 6 | $108 |
| Pfizer | 8 | $92 |
| Sanofi | 5 | $90 |
| Abbott | 5 | $84 |
| Astellas Pharma US Inc | 3 | $45 |
| Merck | 3 | $34 |
| Sunovion Pharmaceuticals Inc. | 2 | $33 |
| Sanofi Pasteur Inc. | 1 | $28 |
| Johnson & Johnson | 2 | $24 |
| Nalpropion Pharmaceuticals LLC | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Medtronic | 1 | $15 |
| Organon | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Radius Health, Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Biogen | 1 | $11 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$4,325 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 166 | $181,846 |
| MounjaroTirzepatide | 144 | $164,167 |
| EliquisApixaban | 123 | $112,312 |
| JanuviaSitagliptin Phosphate | 68 | $88,553 |
| OzempicSemaglutide | 83 | $84,774 |
| TrulicityDulaglutide | 69 | $83,167 |
| RybelsusSemaglutide | 24 | $36,910 |
| XareltoRivaroxaban | 35 | $27,942 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 47 | $26,694 |
| FarxigaDapagliflozin Propanediol | 33 | $24,641 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 70 | $15,345 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 28 | $14,212 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $11,379 |
| PremarinEstrogens, Conjugated | 17 | $8,756 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 236 | $7,678 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $12 | $181,846166 claims |
| PfizerEliquis, Premarin, Paxlovid | $92 | $125,255172 claims |
| Novo NordiskOzempic, Rybelsus | $190 | $121,684107 claims |
| MerckJanuvia | $34 | $88,55368 claims |
| GSKAnoro Ellipta, Shingrix | $170 | $42,039117 claims |
| Johnson & JohnsonXarelto | $24 | $27,94235 claims |
| AstraZenecaFarxiga | $124 | $24,64133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Franklin
- Gaston DanaFranklin$13K
- Abhinav SinghGreenwood$733K
- Girish KunapareddyTerre Haute$329K
- Raj VuppalanchiIndianapolis$279K
- Joseph Arulandula Porte$251K
- Napoleon MamintaIndianapolis$116K
- Jennifer PaisleyLawrenceburg$112K
- Allon FriedmanIndianapolis$111K
- John AyresIndianapolis$107K
- Emily FrankLebanon$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.